JTT-751 for Treatment of Patients with Hyperphosphatemia on Peritoneal Dialysis

Background/Aims: JTT-751 (ferric citrate hydrate) is a novel iron-based phosphate approved in Japan for the treatment of hyperphosphatemia in dialysis and nondialysis patients with chronic kidney disease. Methods: In this phase 3, multicenter, open-label, dose-adjusted study, we investigated the efficacy and safety of JTT-751 in peritoneal dialysis patients. A total of 56 patients with serum phosphate ≥5.6 and
Source: Nephron Clinical Practice - Category: Urology & Nephrology Source Type: research